Serina Therapeutics (SER) EBIT (2018 - 2026)

Serina Therapeutics has disclosed EBIT across 9 years of filings, most recently posting -$6.8 million for Q2 2026.

• In Q2 2026, EBIT fell 21.9% year-over-year to -$6.8 million; the TTM figure through Jun 2026 stood at -$24.9 million (down 11.95% YoY), while the FY2025 annual figure was -$24.0 million, down 40.91% from the prior year.
• EBIT came in at -$6.8 million for Q2 2026 at Serina Therapeutics, down from -$6.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $241000.0 in Q4 2023 to a low of -$6.8 million in Q2 2026.
• Average EBIT over 5 years is -$3.4 million, with a median of -$2.3 million recorded in 2024.
• Year-over-year, EBIT jumped 113.52% in 2023 and slumped 2402.49% in 2024.
• Over 5 years, EBIT stood at -$1.8 million in 2022, then jumped by 113.52% to $241000.0 in 2023, then tumbled by 2402.49% to -$5.5 million in 2024, then declined by 11.86% to -$6.2 million in 2025, then decreased by 9.3% to -$6.8 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$6.8 million in Q2 2026, -$6.2 million in Q4 2025, and -$6.4 million in Q3 2025.